I called SIBI and was warmly greeted.
Away from my notes right now, but.........
Sorry, absolutely *no* guidance being given for royalties ass'd with the Lilly option, to analysts or otherwise. I will therefore use 20% for my estimates.
The company has, on a couple of occasions, indicated that the phase II results for 1508Y would be available Q2. That's 27 days and counting, so I checked. Yup..... they are into the "iterative process" of data evaluation, and plan to report this month.
An outline from the annual meeting (slide copies) indicates that further partnering is expected this year. Discussions are ongoing with more than one company for both apoptosis and VGCC. I specifically asked about VGCC, and was left with the impression that apoptosis might be hotter. This was my impression only, and does not reflect something that I was told.
A couple of genomics/pharma efforts (JNJ and Novartis) have set up in town, and companies are having chemists (and others) picked off. Despite this, SIBI has filled in behind those who have left, and the indication was that morale is strong.
The BMY program........ same story..... expected to hear of clinical plans soon.
Novartis program........ Novartis, as some will recognize, is a very secretive company. I like this, but it leaves the biotech partner wandering around blind. Indications are that the SIBI programs have momentum, particularly "pain".
The Lilly deal...... 25 FTEs at SIBI. Indication was that equivalent staffing is expected on the Lilly side. Big push.
If I sensed any downside, it was uncertainty regarding one of two or both Novartis compounds. This might reflect reality, and it might reflect my imagination.
More later. |
